INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM

Short-term creatine supplementation and repeated sprint ability – a systematic review and meta-analysis

Journal:	International Journal of Sport Nutrition & Exercise Metabolism					
Manuscript ID	IJSNEM.2022-0072.R2					
Manuscript Type:	Scholarly Review					
Keywords:	sprinting, multiple sprint, ergogenic, phosphocreatine					



1	SHORT-TERM CREATINE SUPPLEMENTATION AND REPEATED SPRINT ABILITY – A
2	SYSTEMATIC REVIEW AND META-ANALYSIS
3	
4	RUNNING HEAD TITLE: Creatine and repeated sprint ability
5	
6	MARK GLAISTER ¹ & LAUREN RHODES ¹
7	¹ Faculty of Sport, Allied Health, and Performance Sciences, St Mary's University, Strawberry Hill,
8	Twickenham, TW1 4SX, UK.
9	
10	Corresponding Author
11	Mark Glaister
12	Faculty of Sport, Allied Health, and Performance Sciences
13	St Mary's University
14	Strawberry Hill
15	Twickenham, UK
16	TW1 4SX
17	Tel: (+44)208 240 4012
18	E-mail: mark.glaister@stmarys.ac.uk
19	
20	

21 ABSTRACT

22 The aim of this study was to conduct a systematic review and meta-analysis of the effects of 23 short-term creatine supplementation on repeated sprint ability. Fourteen studies met the inclusion 24 criteria of adopting double-blind randomized placebo-controlled designs in which participants (age: 18 - 60 years) completed a repeated sprint test (number of sprints: $4 < n \le 20$; sprint duration: ≤ 10 s; 25 recovery duration: ≤ 90 s) before and after supplementing with creatine or placebo for 3 – 7 days in a 26 27 dose of $\sim 20 \text{ g} \cdot \text{d}^{-1}$. No exclusion restrictions were placed on the mode of exercise. Meta-analyses were 28 completed using random-effects models, with effects on measures of peak power output, mean power 29 output, and fatigue (performance decline) during each repeated sprint test presented as standardized mean difference (δ); and with effects on body mass and post-test blood lactate concentration presented 30 as raw mean difference (D). Relative to placebo, creatine resulted in a significant increase in body mass 31 (D = 0.79 kg; p < 0.00001) and mean power output ($\delta = 0.61; p = 0.002$). However, there was no effect 32 of creatine on measures of peak power ($\delta = 0.41$; p = 0.10), fatigue ($\delta = 0.08$; p = 0.61), or post-test 33 blood lactate concentration ($D = 0.22 \text{ L} \cdot \text{min}^{-1}$; p = 0.60). In conclusion, creatine supplementation may 34 35 increase mean power output during repeated sprint tests; though the absence of corresponding effects on peak power and fatigue means that more research, with measurements of intramuscular creatine 36 37 content, is necessary to confirm.

38

39 Key words: Sprinting; multiple sprint; ergogenic; phosphocreatine

40 INTRODUCTION

Creatine supplementation, often in the form of creatine monohydrate, is a popular performance 41 42 aid used by athletes. During intense, short duration exercise, the rate of adenosine trisphosphate (ATP) 43 regeneration is largely dependent upon intramuscular phosphocreatine (PCr) availability (Buford et al., 44 2007). To maintain energy and allow maximal effort activity to be continued, ATP regeneration must be close to the rate of ATP hydrolysis (Maughan, 1995). Transfer of the phosphate group from PCr to 45 adenosine diphosphate restores ATP, providing a short-term energy buffer. As PCr stores are limited, 46 47 depletion results in a diminished ability to resynthesise ATP at the rate required to maintain highintensity activity. Consequently, increasing muscle creatine content via creatine supplementation is 48 49 proposed to increase PCr availability, thus accelerating the rate of ATP restoration and allowing a greater amount of work to be completed (Buford et al., 2007; Glaister et al., 2006; Maughan, 1995). 50

51 Studies have examined the potential beneficial effects of creatine supplementation on sport and exercise performance (Bemben & Lamont, 2005), with the greatest benefits being suggested for field 52 53 and court sports (multiple sprint sports) due to their intermittent activity patterns (Kreider et al., 2017; 54 Wax et al., 2021). One of the reasons given for this suggested benefit is that creatine supplementation 55 results in an increased muscle creatine concentration, which possibly enhances the rate of between-56 sprint PCr resynthesis by potentiating the rate of flux through the creatine kinase reaction at the 57 mitochondrial membrane (Casey & Greenhaff, 2000). Since the rate of PCr resynthesis is related to the recovery of power output (Bergström & Hultman, 1991; Bogdanis et al., 1995; Hitchcock, 1989; Sahlin 58 59 & Ren, 1989), it is reasoned that creatine supplementation could enable better recovery between successive sprints, resulting in an overall improvement in performance (or repeated sprint ability) 60 61 (Glaister et al., 2006; Yquel et al., 2002). However, the results of studies examining the effects of creatine supplementation on post-exercise PCr resynthesis rates are inconsistent (Delecluse et al., 2003; 62 Francaux et al., 2000; Greenhaff et al., 1994; Kreis et al., 1999; Preen et al., 2001; Smith et al., 1999; 63 Vandenberghe et al., 1999; Yquel et al., 2002); with most showing either no effect (Delecluse et al., 64 65 2003; Francaux et al., 2000; Kreis et al., 1999; Smith et al., 1999; Vandenberghe et al., 1999), or an effect after the first minute of recovery only (Greenhaff et al., 1994; Preen et al., 2001). Furthermore, 66

investigations into the efficacy of creatine supplementation on eliciting improvements in repeated sprint
ability, typical of that experienced in multiple sprint sports, present conflicting findings (see Glaister et
al., 2006). Therefore, although creatine is often recommended to multi-sprint sport (soccer, rugby,
basketball, volleyball, etc.) athletes as a performance aid, its ergogenic effect remains unclear. The aim
of this systematic review and meta-analysis was therefore to examine the effects of short-term creatine
supplementation on the repeated sprint ability typical of that experienced in multiple sprint sports.

73

74 MATERIALS AND METHODS

75 Systematic review

76 This systematic review was conducted according to the guidelines proposed in the PRISMA 77 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (Moher et al., 2009). 78 The study was registered with Open Science Framework (10.17605/OSF.IO/NT734). The databases of 79 Pubmed, SPORTDiscus, and Web of Science were searched for peer-reviewed publications (prior to 80 June 2022) containing 'creatine' (but not 'creatine kinase') and 'sprint' in the title or the abstract, along with the words 'repeated' or 'multiple', or 'intermittent'. Reference lists of those studies that passed the 81 initial screening for potential inclusion in the analysis were also examined for publications which may 82 have eluded the online database search. 83

84

85 Inclusion and exclusion criteria

Studies considered for inclusion in this investigation were limited to those conducted on adult (18 - 60 years of age) humans using randomized, double-blind, placebo-controlled designs (an exception to the age restriction was made for the study by Deminice et al. (2013) on under-20 soccer players, as the mean age was 17.4 ± 1.2 years for the placebo group and 17.1 ± 1.4 years for the creatine group, and there is no evidence that this margin of age difference influences the acute responses to creatine supplementation). Although the four-week washout period for creatine, following

92 supplementation, favors between-group designs, there are several crossover studies and, as such, both approaches were included in the analysis. The method of creatine supplementation was restricted to the 93 standard short-term loading dose of at least 20 g of creatine per day for 3 - 7 days. To qualify as a test 94 of repeated sprint ability, protocols were restricted to those consisting of a series ($4 \le n \le 20$) of short 95 96 (\leq 10 s) maximal sprints interspersed with fixed-duration rest periods of \leq 90 s (Girard et al., 2011). 97 Performance responses were limited to those used typically to determine repeated sprint ability, namely: 98 peak power output/fastest sprint time, mean power output/sprint time, and fatigue (Glaister, 2008). 99 Research quality (risk of bias) was evaluated by means of the Physiotherapy Evidence Database 100 (PEDro) scale, which ranks the quality of research, via a series of questions, on a 10-point scale 101 (Verhagen et al., 1998). The scale evaluates aspects relating to eligibility criteria, treatment blinding 102 and randomisation, participant matching at baseline, participant completion rate, method of statistical 103 comparison, and the magnitude of any effects. Publications achieving a PEDro score < 6 were 104 considered to lack sufficient quality to be included in the meta-analysis (Ganio et al., 2009).

105

106 Data extraction

Data were extracted independently by two reviewers from relevant publications as means, 107 108 standard deviations (SD), and sample sizes. In instances where data were presented in a graphical format, images were enlarged to improve the precision of the data estimates. Given that the 109 intramuscular uptake of creatine following supplementation is reflected in an increase in body mass 110 (Branch, 2003), data on the effects of creatine on body mass were extracted. In addition, since there is 111 112 some evidence that an increased availability of PCr in a repeated sprint test may lead to a reduction in 113 anaerobic glycolysis (Balsom et al., 1993), data on the effects of creatine supplementation on post-test 114 blood lactate concentration [BLa] were also collated. For all study designs, data were extracted for baseline (T_{base}) and post-supplementation (T_{post}) responses for both creatine and placebo 115 116 groups/conditions. Data from sprint running tests of repeated sprint ability were converted to power 117 outputs in line with previous research (Zagatto et al., 2009) using Equation 1.

118

Equation 1. power output = (body mass (kg) × distance $(m)^2$)/time $(s)^3$.

119 Meta-analysis

120 The database search (Figure 1) returned 172 articles (Pubmed, n = 55; SPORTDiscus, n = 57; Web of Science, n = 60), which, after the removal of duplicates (n = 93), the addition of articles acquired 121 from the search of reference lists (n = 1), and the removal of studies which failed to meet the inclusion 122 123 criteria (n = 66), left 14 studies for the meta-analysis (Table 1). Meta-analyses were conducted using specialist software (Review Manager Version 5.3. The Nordic Cochrane Centre, Copenhagen: The 124 Cochrane Collaboration, 2014). Meta-analyses were completed using random-effects models, with 125 effects on measures of peak power output, mean power output, and fatigue during each repeated sprint 126 127 test presented as standardized mean difference (δ) and with effects on body mass and post-test [BLa] presented as raw mean difference (D) (i.e. the difference between the raw mean values of the creatine 128 and placebo conditions). 95% confidence limits (CL₉₅) were calculated for all estimates. Given the 129 130 failure of studies using between-group designs to report T_{base} – T_{post} change scores, mean changes from 131 baseline in placebo and creatine groups for each dependent variable were calculated using Equation 2, with standard deviations of those changes (SDA) imputed using Equation 3 (Higgins et al., 2008). The 132 same approach was used for studies adopting crossover designs to allow between- and within-study 133 134 designs to be included in the same analyses.

135

Equation 2. mean difference = mean post – mean baseline

136 Equation 3.
$$SD\Delta = [(SD_{base})^2 + (SD_{post})^2 - 2 \times corr(T_{base}, T_{post}) \times SD_{base} \times SD_{post}]^{0.5}$$

137 Note: $corr(T_{base}, T_{post})$ is the correlation between T_{base} and T_{post} values and was calculated for all 138 dependent variables, apart from post-test [Bla], using the raw data of Glaister et al. (2006) (see Table 139 2). In contrast, for post-test [Bla], SD Δ was imputed using a conservative corr(T_{base}, T_{post}) estimate of 140 0.5 for both creatine and placebo responses (Higgins & Green, 2008).

141 Heterogeneity between studies was examined using the l^2 statistic, which describes the 142 percentage of variability in mean difference estimates due to heterogeneity rather than chance. When l^2 143 was > 25% (25 – 50% represents moderate heterogeneity (Higgins et al., 2003)), a subgroup metaanalysis was completed to investigate the source of heterogeneity. In line with recommendations 144 regarding tests for heterogeneity (Ioannidis et al., 2007), CL₉₅ for P were calculated using the method 145 outlined by Higgins and Thompson (2002). Subgroup meta-analyses were performed, when appropriate, 146 147 to investigate the influence of exercise mode as a potential moderator variable. In contrast, no subgroup analyses were conducted to investigate the effects of either: 1) sex - since most studies used male 148 149 participants; or 2) training status – since between-study inconsistences in the way that this variable was 150 reported/measured did not allow quantification with adequate precision. Heterogeneity between subgroups was also evaluated using the I^2 statistic. Publication bias was evaluated through visual 151 152 inspection of funnel plots. Statistical significance was accepted at p < 0.05 for all analyses.

153

FIGURE 1. ABOUT HERE.

154 RESULTS

A summary of the findings from each of the studies that met the inclusion criteria, including 155 the risk-of-bias assessment, is presented in Table 1. All the studies that met the inclusion criteria passed 156 the risk-of-bias assessment (Table 1) and there was no evidence of asymmetry (publication bias) in any 157 of the funnel plots. The mean age of participants in each of the studies was < 30 years, with the oldest 158 being 28.4 ± 0.7 years (Kamber et al., 1999). Seven of the studies stated that participants were non-159 vegetarian with the remainder providing no comment. Apart from the studies by Ahmun et al. (2005), 160 Deminice et al. (2013), and Mujika et al. (2000), creatine was ingested with carbohydrate to increase 161 the insulin response and facilitate a greater intramuscular uptake of creatine (Casey & Greenhaff, 2000). 162 163 However, none of the studies measured T_{base} - T_{post} changes in muscle creatine content.

- 164
- 165

TABLE 1. ABOUT HERE.

TABLE 2. ABOUT HERE.

166

167 Body mass

168	Relative to placebo, there was a significant increase in body mass following creatine
169	supplementation (Figure 2) ($D = 0.79$ kg; CL ₉₅ [0.55, 1.03]; $p < 0.00001$). There was also evidence of a
170	moderate degree of heterogeneity between the studies ($I^2 = 40\%$; CL ₉₅ [0, 70]).
171	
470	
172	FIGURE 2. ABOUT HERE.
173	
174	Peak power output
175	The effect of supplementation on peak power output during the repeated sprint tests is presented
176	in Figure 3. Relative to placebo, creatine had no effect on peak power output ($\delta = 0.41$; CL ₉₅ [-0.08,
177	0.90]; $p = 0.10$). Despite a large degree of heterogeneity between studies ($l^2 = 75\%$; CL ₉₅ [58, 85]),
178	subgroup analyses were unable to attribute that heterogeneity to between-study differences in mode of
179	exercise ($l^2 = 0\%$; $p = 0.80$). Large degrees of heterogeneity in peak power output remained in cycling
180	$(l^2 = 71\%; CL_{95}[32, 88])$ and running $(l^2 = 79\%; CL_{95}[59, 89])$ based studies, and the absence of any
181	significant effects of creatine on peak power output remained in both sprint cycling ($\delta = 0.34$; CL ₉₅ [-
182	0.40, 1.08]; $p = 0.37$) and sprint running ($\delta = 0.47$; CL ₉₅ [-0.22, 1.15]; $p = 0.18$) protocols.
183	
184	FIGURE 3. ABOUT HERE.
185	
186	Mean power output
187	Seven of the studies included in this review reported mean power output in their analysis
188	(Figure 4). Relative to placebo, creatine supplementation increased mean power output by 27 ± 20 W
189	$(\delta = 0.61; CL_{95}[0.23, 1.00]; p = 0.002)$, with a moderate degree of between-study heterogeneity ($l^2 =$

190 27%; $CL_{95}[0, 68]$). Subgroup comparisons revealed significant effects of creatine on mean power output

191 in sprint cycling ($\delta = 0.82$; CL₉₅[0.19, 1.45]; p = 0.01) but not in sprint running ($\delta = 0.49$; CL₉₅[-0.01,

192	0.99]; $p = 0.06$) protocols. Despite moderate degrees of heterogeneity in the cycling- ($l^2 = 27\%$; CL ₉₅ [0,
193	95]) and running-based ($l^2 = 33\%$; CL ₉₅ [0, 76]) studies, there was no evidence of heterogeneity between
194	those subgroups ($I^2 = 0\%$; $p = 0.43$).
195	
196	FIGURE 4. ABOUT HERE.
197	
198	Fatigue
199	The effects of supplementation on measures of fatigue during the repeated sprint tests are
200	presented in Figure 5. Relative to placebo, there was no effect of creatine on fatigue ($\delta = 0.08$; CL ₉₅ [-
201	0.22, 0.37]; $p = 0.61$) and there was no evidence of heterogeneity between the studies ($l^2 = 0\%$; CL ₉₅ [0,
202	71]).
203	
204	FIGURE 5. ABOUT HERE.
205	
206	Blood lactate
207	Seven studies reported a measure of post-test [BLa] (Figure 6). Relative to placebo, there was
208	no effect of creatine on post-test [BLa] ($D = 0.22 \text{ L} \cdot \text{min}^{-1}$; CL ₉₅ [-0.59, 1.03]; $p = 0.60$) and no evidence
209	of between-study heterogeneity ($I^2 = 0\%$; CL ₉₅ [0, 71]).
210	
211	FIGURE 6. ABOUT HERE.
212	
213	DISCUSSION

The aim of this systematic review and meta-analysis was to examine the effects of creatine supplementation on repeated sprint ability. The key findings were that creatine increased body mass and mean power output, but had no effect on peak power output, fatigue, or post-test [BLa]. Moreover, the effect of creatine on mean power output appeared to be constrained to those studies which used cycling as the mode of exercise.

219

220 The increase in body mass following short-term creatine supplementation is similar to that reported previously (Branch, 2003) and is attributed mostly to an increase in fluid retention resulting 221 from the osmotic pressure caused by the intramuscular uptake of creatine (Casey & Greenhaff, 2000; 222 223 Juhn & Tarnopolsky, 1998; Ziegenfuss et al., 2002). Nevertheless, there was considerable betweenstudy heterogeneity in the magnitude of the response, with five of the studies reporting no significant 224 effect of creatine on body mass (see Table 1). The large degree of heterogeneity is most likely the result 225 of considerable between-subject variability in creatine uptake following supplementation, with reports 226 227 that approximately 20 - 30% of individuals experience an increase in intramuscular creatine content of 228 less than 10 mmol.kg dm⁻¹, and are classified, therefore, as 'non-responders' (Greenhaff, 1997; Greenhaff et al., 1994; Syrotuik & Bell, 2004). However, it is difficult to draw any firm conclusions 229 about the cause of the variability in body mass changes since none of the studies measured $T_{base} - T_{post}$ 230 231 change scores in muscle creatine content.

232

The absence of any significant effect of creatine supplementation on peak power output during the repeated sprint tests is not surprising given that peak power output occurs within the first few sprints (often in the first sprint), and that PCr stores are not considered to be limited at that time (Gaitanos et al., 1993). Indeed, PCr is reported to contribute approximately 50% to ATP resynthesis in the first of 10×6 s sprints (30 s rest periods), depleting stores by approximately 50% (Gaitanos et al., 1993). In contrast, the significant effect of creatine supplementation on mean power output suggests that the increased availability of creatine is able to offset partially the shortfall in PCr as sprints are repeated, 240 and/or that increased creatine availability is facilitating faster recovery of PCr between successive sprints. As highlighted earlier, if the response on mean power output is due to faster PCr recovery 241 between sprints, it is strange that most studies investigating the effects of creatine supplementation on 242 PCr recovery kinetics have failed to show any effect; particularly in the relatively short recovery time-243 244 frame typical of tests of repeated sprint ability (Glaister et al., 2006). Nevertheless, the increase in mean 245 power output in the absence of any significant change in post-exercise [BLa] supports the idea that the 246 increase in mean power output was due to an increased contribution from PCr to ATP resynthesis as 247 the repeated sprint tests progressed.

248

Although the results of the meta-analysis revealed a significant effect of creatine on mean power output, it seems strange that there was no corresponding effect on the fatigue response; particularly given the absence of any effect of creatine on peak power output during the repeated sprint tests. Then again, there are many ways to quantify fatigue in repeated sprint tests and all show relatively poor test-retest reliability (Glaister et al., 2008). In effect, it may be that the fatigue calculations used by the studies included in this review lacked sufficient sensitivity to detect changes in repeated sprint ability of the magnitude possible from creatine supplementation.

256

It would be easy to attribute the results of the subgroup analysis on mean power output to the 257 effects of body mass changes on weight-bearing (running) versus non-weightbearing (cycling) 258 protocols; particularly if the gain in body mass is due to fluid retention. However, there are some 259 problems with that argument. First, the analysis showed that the moderate degree of heterogeneity 260 261 remained regardless of whether studies were cycling- or running-based; secondly, there were no differences in heterogeneity between the subgroups; and thirdly, there was no corresponding effect on 262 263 peak power output. As such, while it is possible that a creatine-induced increase in body mass may have 264 counteracted any positive effect on sprint running performance, further research is required to clarify.

265

266 Limitations

There are a few limitations associated with this review which should be highlighted. First, 267 despite a reasonable number of studies meeting the inclusion criteria, the number measuring mean 268 269 power output, fatigue, and [BLa] in the repeated sprint tests was relatively small, making it difficult to 270 form clear conclusions about those responses (particularly when investigating subgroup differences); secondly, the measurement of data from graphical representations for each meta- analysis may have 271 272 introduced some error into the precision of the estimates; thirdly, the failure of studies to report the 273 standard deviations of T_{base} - T_{post} change scores, a common problem in meta-analyses of betweengroup designs (Pearson & Smart, 2018), meant that values had to be imputed, thereby introducing a 274 275 potential source of error into each analysis; thirdlyfourthly, Tarnopolsky and MacLennan (2000) 276 proposed that independent groups should contain at least 20 participants in each to avoid the potential 277 for making a Type II statistical error. However, most of the independent group design studies included 278 in this review failed to meet that recommendation; and lastly, given the difficulties of accurately quantifying muscle creatine content, the failure of studies to measure $T_{\text{base}} - T_{\text{post}}$ change scores in 279 280 muscle creatine content means that the true effects of creatine supplementation on repeated sprint ability Lien 281 remain largely uncertain.

282

Conclusions 283

The results of this analysis show that short-term creatine supplementation increases mean 284 power output in a repeated sprint test, though the absence of a corresponding effect on fatigue means 285 that more research is required to confirm. The effect on mean power output also appears to be dependent 286 on the mode of exercise, with the positive effect on sprint running protocols possibly being offset by 287 the gain in body mass associated with creatine supplementation. In contrast, creatine had no effect on 288 289 peak power output. Research into the effects of creatine supplementation continues to be blighted by 290 the failure of studies to measure T_{base} - T_{post} change scores in muscle creatine content and, until this

issue is addressed, it is difficult to draw any firm conclusions about the effects of creatine on repeatedsprint ability.

293

294 Author contributions

Mark Glaister (MG) and Lauren Rhodes (LR) wrote the introduction and performed the literature search. Both authors independently checked the literature for relevant papers. MG extracted the data on all the key variables and LR checked those data for accuracy. MG and LR conducted the review of research quality of included articles. MG converted all the performance data to power outputs and wrote the corresponding sections in the paper. MG conducted the meta-analyses on the key variables and wrote the corresponding methods and results sections. MG and LR wrote the discussion section of the review. All authors read and approved the final version of the manuscript.

302

303 Conflicts of interest

304 The authors declare no conflicts of interest. The authors alone are responsible for the content and writing

305 of the article.

306 **References**

307	Ahmun, R., Tong, R., & Grimshaw, P. (2005). The effects of acute creatine supplementation on multiple
308	sprint cycling and running performance in rugby players. Journal of Strength and Conditioning
309	Research, 19(1), 92-97. doi: 10.1519/13573.1
310	Balsom, P., Ekblom, B., Söderlund, K., Sjödin, B., & Hultman, E. (1993). Creatine supplementation
311	and dynamic high-intensity intermittent exercise. Scandinavian Journal of Medicine & Science
312	in Sports, 3(3), 143-149. doi: 10.1111/j.1600-0838.1993.tb00378.x
313	Barnett, C., Hinds, M., & Jenkins, D. (1996). Effects of oral creatine supplementation on multiple sprint
314	cycle performance. The Australian Journal of Science & Medicine in Sport, 28(1), 35-39.
315	PMID: 8742865
316	Bemben, M., & Lamont, H. (2005). Creatine supplementation and exercise performance. Sports
317	Medicine, 35(2), 107-125. doi: 10.2165/00007256-200535020-00002
318	Bergström, M., & Hultman, E. (1991). Relaxation and force during fatigue and recovery of the human
319	quadriceps muscle: relations to metabolite changes. Pflügers Archiv: European Journal of
320	<i>Physiology</i> , <i>418</i> (1-2), 153-160. doi: 10.1007/BF00370464
321	Bogdanis, G., Nevill, M., Boobis, L., Lakomy, H., & Nevill, A. (1995). Recovery of power output and
322	muscle metabolites following 30 s of maximal sprint cycling in man. Journal of Physiology,
323	482(2), 467-480. doi: 10.1113/jphysiol.1995.sp020533
324	Branch, J. (2003). Effect of creatine supplementation on body composition and performance: a meta-
325	analysis. International Journal of Sport Nutrition & Exercise Metabolism, 13(2), 198-226. doi:
326	10.1123/ijsnem.13.2.198
327	Buford, T., Kreider, R., Stout, J., Greenwood, M., Campbell, B., Spano, M., Ziegenfuss, T., Lopez, H.,
328	Landis, J., & Antonio, J. (2007). International Society of Sports Nutrition position stand:

329	creatine supplementation and exercise. Journal of the International Society of Sports Nutrition,
330	4(1), 6. doi: 10.1186/1550-2783-4-6
331	Casey, A., & Greenhaff, P. (2000). Does dietary creatine supplementation play a role in skeletal muscle
332	metabolism and performance? The American Journal of Clinical Nutrition, 72(2), 607S-617S.
333	doi: 10.1093/ajcn/72.2.607S
334	Dawson, B., Cutler, M., Lawrence, S., Goodman, C., & Randall, N. (1995). Effects of oral creatine
335	loading on single and repeated maximal short sprints. Australian Journal of Science & Medicine
336	in Sport, 27(3), 56-61. PMID: 8599745
337	Delecluse, C., Diels, R., & Goris, M. (2003). Effect of creatine supplementation on intermittent sprint
338	running performance in highly trained athletes. Journal of Strength & Conditioning Research,
339	17(3), 446-454. doi: 10.1519/1533-4287(2003)017<0446:eocsoi>2.0.co;2
340	Deminice, R., Rosa, F.T., Franco, G.S., Jordao, A.A., & de Freitas, E.C. (2013). Effects of creatine
341	supplementation on oxidative stress and inflammatory markers after repeated-sprint exercise in
342	humans. Nutrition, 29(9),1127-1132. doi: 10.1016/j.nut.2013.03.003
343	Francaux, M., Demeure, R., Goudemant, J., & Poortmans, J. (2000). Effect of exogenous creatine
344	supplementation on muscle PCr metabolism. International Journal of Sports Medicine, 21(2),
345	139-145. doi: 10.1055/s-2000-11065
346	Gaitanos, G., Williams, C., Boobis, L., & Brooks, S. (1993). Human muscle metabolism during
347	intermittent maximal exercise. Journal of Applied Physiology, 75(2), 712-719. doi:
348	10.1152/jappl.1993.75.2.712
349	Ganio, M.S., Klau, J.F., Casa, D.J., Armstrong, L.E., & Maresh, C.M. (2009). Effect of caffeine on
350	sport-specific endurance performance: a systematic review. Journal of Strength & Conditioning
351	Research, 23(1), 315-324. doi: 10.1519/JSC.0b013e31818b979a

- Girard, O., Mendez-Villanueva, A., & Bishop, D. (2011). Repeated-sprint ability part I: factors
 contributing to fatigue. *Sports Medicine*, *41*(8), 673-694. doi: 10.2165/11590550-00000000000000.
- Glaister, M. (2008). Multiple sprint work: methodological, physiological, and experimental issues. *International Journal of Sports Physiology & Performance, 3*(1), 106-111. doi:
 10.1123/ijspp.3.1.107
- Glaister, M., Howatson, G., Pattison, J.R., & McInnes, G. (2008). The reliability and validity of fatigue
 measures during multiple sprint work: an issue revisited. *Journal of Strength & Conditioning Research*, 22(5), 1597-1601. doi: 10.1519/JSC.0b013e318181ab80
- Glaister, M., Lockey, R., Abraham, C., Staerck, A., Goodwin, J., & McInnes, G. (2006). Creatine
 supplementation and multiple sprint running performance. *Journal of Strength & Conditioning Research, 20*(2), 273-277. doi: 10.1519/R-17184.1
- Greenhaff, P.L. (1997). The nutritional biochemistry of creatine. *Journal of Nutritional Biochemistry*,
 8(11), 610-618. https://doi.org/10.1016/S0955-2863(97)00116-2
- Greenhaff, P.L., Bodin, K., Söderlund, K., & Hultman, E. (1994). Effect of oral creatine
 supplementation on skeletal muscle phosphocreatine resynthesis. *The American Journal of Physiology 266*(5), 725-730. doi: 10.1152/ajpendo.1994.266.5.E725
- Griffen, C., Rogerson, D., Ranchordas, M., & Ruddock, A. (2015). Effects of creatine and sodium
 bicarbonate coingestion on multiple indices of mechanical power output during repeated
 Wingate tests in trained men. *International Journal of Sport Nutrition & Exercise Metabolism,*
- 372 25(3), 298-306. doi: 10.1123/ijsnem.2014-0146
- Higgins, J.P.T., & Green, S. (2008). Cochrane Handbook for Systematic Reviews of Interventions.
 Chichester, UK: John Wiley & Sons.

- Higgins, J.P.T., & Thompson, S.G. (2002). Quantifying heterogeneity in a meta analysis. *Statistics in Medicine*, 21(11), 1539-1558. doi: 10.1002/sim.1186
- Higgins, J.P.T., Thompson, S.G., Deeks, J.J., & Altman, D.G. (2003). Measuring inconsistency in metaanalyses. *British Medical Journal*, *327*(7414), 557-560. doi: 10.1136/bmj.327.7414.557
- 379 Hitchcock, H. (1989). Recovery of short-term power after dynamic exercise. *Journal of Applied* 380 *Physiology*, 67(2), 677-681. doi: 10.1152/jappl.1989.67.2.677
- Ioannidis, J.P.A., Patsopoulos, N.A., & Evangelou, E. (2007). Uncertainty in heterogeneity estimates
 in meta-analyses. *British Medical Journal*, 335(7626), 914-916. doi:
 10.1136/bmj.39343.408449.80
- Izquierdo, M., Ibañez, J., González-Badillo, J.J., & Gorostiaga, E.M. (2002). Effects of creatine
 supplementation on muscle power, endurance, and sprint performance. *Medicine & Science in Sports & Exercise, 34*(2), 332–343. doi: 10.1097/00005768-200202000-00023
- Juhn, M.S., & Tarnopolsky, M. (1998). Oral creatine supplementation and athletic performance: a
 critical review. *Clinical Journal of Sports Medicine*, 8(4), 286-297. doi: 10.1097/00042752199810000-00006
- Kamber, M., Koster, M., Kreis, R., Walker, G., Boesch, C., & Hoppeler, H. (1999). Creatine
 supplementation part I: Performance, clinical chemistry, and muscle volume. *Medicine & Science in Sports & Exercise, 31*(12), 1763–1769. doi: 10.1097/00005768-199912000-00011
- Kinugasa, R., Akima, H., Ota, A., Ohta, A., Sugiura, K., & Kuno, S.Y. (2004). Short-term creatine
 supplementation does not improve muscle activation or sprint performance in humans.
 European Journal of Applied Physiology, *91*(2-3), 230-237. doi: 10.1007/s00421-003-0970-8
- Kreider, R., Kalman, D., Antonio, J., Ziegenfuss, T., Wildman, R., Collins, R., Candow, D.G., Kleiner,
 S.M., Almada, A.L., & Lopez, H.L. (2017). International Society of Sports Nutrition position

398	stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal
399	of the International Society of Sports Nutrition, 14,18. doi: 10.1186/s12970-017-0173-z

- Kreis, R., Kamber, M., Koster, M., Felblinger, J., Slotboom, J., Hoppeler, H., Boesch, C. (1999).
 Creatine supplementation part II: in vivo magnetic resonance spectroscopy. *Medicine & Science in Sports & Exercise, 31*(12), 1770–1777. doi: 10.1097/00005768-199912000-00012
- Maughan, R. (1995). Creatine supplementation and exercise performance. *International Journal of Sport Nutrition*, 5(2), 94-101. doi: 10.1123/ijsn.5.2.94
- Moher, D., Liberati, A., Tetzlaff, J., & Altman, D.G. (2009). The PRISMA Group. Preferred reporting
 items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*,
 6:e1000097. doi: 10.1371/journal.pmed.1000097.
- Mujika, I., Padilla, S., Ibanez, J., Izquierdo, M., & Gorostiaga, E. (2000). Creatine supplementation and
 sprint performance in soccer players. *Medicine & Science in Sports & Exercise, 32*(2), 518525. doi: 10.1097/00005768-200002000-00039
- Pearson, M.J., Smart, N.A. (2018). Reported methods for handling missing change standard deviations
 in meta-analyses of exercise therapy interventions in patients with heart failure: A systematic
 review. *PLoS One*, e0205952. doi: 10.1371/journal.pone.0205952
- 414 Preen, D., Dawson, B., Goodman, C., Lawrence, S., Beilby, J., & Ching, S. (2001). Effect of creatine
 415 loading on long-term sprint exercise performance and metabolism. *Medicine & Science in*416 *Sports & Exercise*, 33(5), 814-821. doi: 10.1097/00005768-200105000-00022
- Sahlin, K., & Ren, J. (1989). Relationship of contraction capacity to metabolic changes during recovery
 from a fatiguing contraction. *Journal of Applied Physiology*, 67(2), 648-654. doi:
 10.1152/jappl.1989.67.2.648

Skare, O., Skadberg, O., & Wisnes, A. (2001). Creatine supplementation improves sprint performance

421	in male sprinters. Scandinavian Journal of Medicine & Science in Sports, 11(2), 96-102. doi:
422	10.1034/j.1600-0838.2001.011002096.x
423	Smith, S.A., Montain, S.J., Matott, R.P., Zientara, G.P., Jolesz, F.A., & Fielding, R.A. (1999). Effects
424	of creatine supplementation on the energy cost of muscle contraction: a ³¹ P-MRS study. Journal
425	of Applied Physiology, 87(1), 116–123. doi: 10.1152/jappl.1999.87.1.116
426	Syrotuik, D., & Bell, G. (2004). Acute creatine monohydrate supplementation: a descriptive
427	physiological profile of responders vs. nonresponders. Journal of Strength & Conditioning
428	Research, 18(3), 610-617. doi: 10.1519/12392.1
429	Tarnopolsky, M., & MacLennan, D. (2000). Creatine monohydrate supplementation enhances high-
430	intensity exercise performance in males and females. International Journal of Sport Nutrition
431	& Exercise Metabolism, 10(4), 452-463. doi: 10.1123/ijsnem.10.4.452
432	Vandenberghe, K., Van Hecke, P., Van Leemputte, M., Vanstapel, F., & Hespel, P. (1999).
433	Phosphocreatine resynthesis is not affected by creatine loading. Medicine & Science in Sports
434	& Exercise, 31(2), 236–242, 1999. doi: 10.1097/00005768-199902000-00006
435	Verhagen, A.P., de Vet, H.C., de Bie, R.A., Kessels, A.G., Boers, M., Bouter, L.M., Knipschild, P.G.
436	(1998). The Delphi list: a criteria list for quality assessment of randomized clinical trials for
437	conducting systematic reviews developed by Delphi consensus. Journal of Clinical
438	Epidemiology, 51(12), 1235-1241. doi: 10.1016/s0895-4356(98)00131-0
439	Wax, B., Kerksick, C.M., Jagim, A.R., Mayo, J.J., Lyons, B.C., & Kreider, R.B. (2021). Creatine for
440	exercise and sports performance, with recovery considerations for healthy populations.
441	Nutrients, 13(6), 1915. doi: 10.3390/nu13061915.
442	Yquel, R., Arsac, L., Thiaudiere, E., Canioni, P., & Manier, G. (2002). Effect of creatine
443	supplementation on phosphocreatine resynthesis, inorganic phosphate accumulation and pH
	Human Kinetics, 1607 N Market St, Champaign, IL 61825

444 during intermittent maximal exercise. Journal of Sports Sciences, 20(5), 427-437. doi:

10.1080/026404102317366681 445

448

446 Zagatto, A.M., Beck, W.R., & Gobatto, C.A. (2009). Validity of the running anaerobic sprint test for 447 assessing anaerobic power and predicting short-distance performances. Journal of Strength &

Conditioning Research, 23(6), 1820-1827. doi: 10.1519/JSC.0b013e3181b3df32

- Ziegenfuss, T., Rogers, M., Lowery, L., Mullins, N., Mendel, R., Antonio, J., & Lemon, P. (2002). 449
- Effect of creatine loading on anaerobic performance and skeletal muscle volume in NCAA 450 , ικ η, 18(5), .

division I athletes. Nutrition, 18(5), 397-402. doi: 10.1016/s0899-9007(01)00802-4 451

Author(s)	n	n	Sex	Design	Training status	Exercise mode	Sprint protocol	Dose	Dose	Results	PEDro
	(CR)	(PL)			(as described)			(per day)	duration		score
									(days)		
Ahmun et al. 2005	14	14	М	R, DB, XO ^a	Rugby players	Cycling	10 × 6 s; 24 s rest	4 × 5 g	5	No Δ in BM, PPO, or fatigue	10
Ahmun et al. 2005	14	14	М	R, DB, XO ^a	Rugby players	Running (Indoor)	10 × 40 m; 24 s rest	4 × 5 g	5	No Δ in BM, FST, or fatigue	10
Barnett et al. 1996	9	8	М	R, DB, IG, Md	Recreationally active	Cycling	5 × 10 s; 30 s rest	4 × ~5 g	4	No Δ in BM, PPO, MPO, or [BLa]	10
Bogdanis et al. 2022	8	8	М	R, DB, IG	Recreationally active	Running (NMT)	6 × 10 s; 30 s rest	4 × ~5 g	5	\uparrow BM & MPO; No Δ in PPO, or [BLa]; \downarrow fatigue	10
Dawson et al. 1995	11	11	М	R, DB, IG	Healthy active	Cycling	6 × 6 s; 24 s rest	4 × 5 g	5	No Δ in BM or [BLa], or fatigue; \uparrow PPO & MPO	10
Delecluse et al. 2003	9	9	4F; 5M	R, DB, XO ^b	Sprinters	Running (Indoor)	7 × 40 m; 30 s rest	5 × ~4.6 g	7	No Δ in BM, FST, or fatigue	9
Deminice et al. 2013	13	12	М	R, DB, IG	Soccer players	Running (Field)	6 × 35 m; 10 s rest	~21.5 g	7	No Δ in BM, [BLa], or fatigue; \uparrow PPO & MPO	10
Glaister et al. 2006	21	21	М	R, DB, IG, Md	Physically active	Running (Indoor)	15 × 30 m; ~30 s rest	4 × 5 g	5	\uparrow BM; No Δ in FST, MST, [BLa], or fatigue	10
Griffen et al. 2015	9	9	М	R, DB, XO ^c	Well-trained	Cycling	6 × 10 s; 60 s rest	4 × 5 g	7	No Δ in PPO or MPO; \uparrow fatigue	10
Izquierdo et al. 2002	9	10	М	R, DB, IG	Handball players	Running (Indoor)	6 × 15 m; 60 s rest	4 × 5 g	5	\uparrow BM; No Δ in MST	10
Kamber et al. 1999	10	10	М	R, DB, XOª	Well-trained	Cycling	10 × 6 s; 30 s rest	4 × 5 g	5	\uparrow BM and MPO; \downarrow [BLa]	10
Kinugasa et al. 2004	6	6	М	R, DB, IG, Md	Healthy	Cycling	10 × 6 s; 30 s rest	4 × 5 g	5	\uparrow BM; No Δ in PPO, MPO, or [BLa]	10
Mujika et al. 2000	8	9	М	R, DB, IG, Md	Soccer players	Running (Unsure)	6 × 15 m; 30 s rest	4 × 5 g	6	\uparrow BM, No \triangle in [BLa]; unclear for FST and MST	10
Skare et al. 2001	9	9	М	R, SB [*] , IG, Md	Sprinters	Running (Indoor)	6 × 60 m; ~42 s rest	4 × 5 g	5	↑ BM & [BLa]; ↓ MST	10
Ziegenfuss et al. 2002	10	10	10F; 10M	R, DB, IG, Md	Athletes (Collegiate)	Cycling	6 × 10 s; 60 s rest	5 × ~4.3 g	3	↑ BM, PPO, and MPO	10

Table 1. The effects of short-term creatine supplementation ($^{2}0 \text{ g} \cdot d^{-1}$ for 3 – 7 days) on repeated sprint ability (number of sprints: 4 < n ≤ 20; sprint duration: ≤ 10 s; recovery duration: ≤ 90 s) and associated physiological responses.

Note: [↑], significant (*p* < 0.05) increase relative to placebo; [↓], significant (*p* < 0.05) decrease relative to placebo; [BLa], end test blood lactate concentration; BM, body mass; CR, creatine; DB, double-blind; F, female; FST, fastest sprint time; IG, independent groups; M, male; Md, matched at baseline; MST, mean sprint time; NMT, non-motorized treadmill; no Δ, no significant (*p* ≥ 0.05) change relative to placebo; PEDro, Physiotherapy evidence database scale; Phys Ed, physical education; PL, placebo; PPO, peak power output; R, randomized; XO, crossover; ^a28 day washout; ^b49 day washout; ^c35 day washout.

Table 2. Pre – post correlation coefficients for the short-term effects of creatine and placebo supplementation on repeated sprint ability.

Supplement	Body mass	Peak power	Mean power	Fatigue	Post-test [BLa]
Creatine	0.996	0.971	0.960	0.551	0.500*
Placebo	0.994	0.891	0.677	0.558	0.500*

Note: [BLa] = blood lactate concentration. Unless otherwise indicated, values were evaluated from the raw data of Glaister et al. (2006). *Estimated value.

Korper Review

452 Figure Legends

Figure 1. Flow chart of the search strategy used to identify studies examining the effects of short-term creatine supplementation (~20 g·d⁻¹ for 3 – 7 days) on repeated sprint ability (number of sprints: 4 < n ≤ 20 ; sprint duration: ≤ 10 s; recovery duration: ≤ 90 s) and associated physiological responses.

456

Figure 2. A forest plot of studies that have investigated the effects of short-term creatine supplementation on body mass. Squares represent the mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to each response. The diamond at the base of the plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

463

Figure 3. A forest plot of studies that have investigated the effects of short-term creatine 464 465 supplementation on peak power output during a repeated sprint test. Squares represent the standardized mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 466 95% confidence limits. The plot includes subgroup analyses of studies that used cycling versus running 467 468 as the mode of exercise. The size of each square reflects the weighting given to each response. The 469 diamond at the base of the plot (and at the base of each subgroup analysis) represents the overall effect 470 calculated from a random effects model; the width of the diamond representing the 95% confidence 471 interval.

472

473 Figure 4. A forest plot of studies that have investigated the effects of short-term creatine
474 supplementation on mean power output during a repeated sprint test. Squares represent the standardized
475 mean difference in change scores (post supplementation – baseline), relative to placebo, with associated
476 95% confidence limits. The plot includes subgroup analyses of studies that used cycling versus running

as the mode of exercise. The size of each square reflects the weighting given to each response. The
diamond at the base of the plot (and at the base of each subgroup analysis) represents the overall effect
calculated from a random effects model; the width of the diamond representing the 95% confidence
interval.

481

Figure 5. A forest plot of studies that have investigated the effects of short-term creatine supplementation on fatigue percentage during a repeated sprint test. Squares represent the standardized mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to each response. The diamond at the base of the plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

488

Figure 6. A forest plot of studies that have investigated the effects of short-term creatine supplementation on blood lactate concentration at the end of a repeated sprint test. Squares represent the mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to each response. The diamond at the base of the plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.



Figure 1. Flow chart of the search strategy used to identify studies examining the effects of short-term creatine supplementation (~20 g·d⁻¹ for 3 – 7 days) on repeated sprint ability (number of sprints: $4 < n \le 20$; sprint duration: ≤ 10 s; recovery duration: ≤ 90 s) and associated physiological responses.



Figure 2. A forest plot of studies that have investigated the effects of short-term creatine supplementation on body mass. Squares represent the mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to each response. The diamond at the base of the plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

	Cr	eatine		Placebo			:	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.9.1 Cycling									
Ahmun et al. 2005	49	43.7	14	7	69.1	14	7.9%	0.71 [-0.06, 1.47]	
Barnett et al. 1996	13.2	34.5	9	3.2	65.5	8	7.1%	0.18 [-0.77, 1.14]	
Dawson et al. 1995	50	40.1	11	-33.3	70	11	7.1%	1.40 [0.45, 2.36]	
Griffen et al. 2015	147	65.4	9	5	149.6	9	6.8%	1.17 [0.15, 2.19]	_
Kamber et al. 1999	-11	33.1	10	-2	27.7	10	7.4%	-0.28 [-1.16, 0.60]	
Kinugasa et al. 2004	11	18.1	6	51.5	28.7	6	5.5%	-1.56 [-2.92, -0.19]	
Subtotal (95% CI)			59			58	41.8%	0.34 [-0.40, 1.08]	
Heterogeneity: Tau ² =	0.59; Ch	i² = 17	.47, df	= 5 (P =	0.004)	; I ² = 71	.%		
Test for overall effect:	Z = 0.91	(P = 0	.37)						
1.9.2 Running									
Ahmun et al. 2005	46	66.9	14	37	101.5	14	8.0%	0.10 [-0.64, 0.84]	
Bogdanis et al. 2022	-3	26.6	8	-20.8	49.4	8	6.9%	0.42 [-0.57, 1.42]	
Delecluse et al. 2003	28	30.2	9	-5	63	9	7.1%	0.64 [-0.32, 1.59]	
Deminice et al. 2013	76.4	27.1	13	-25.5	60.4	12	6.8%	2.14 [1.12, 3.15]	
Glaister et al. 2006	-24	81.3	21	61	87.3	21	8.3%	-0.99 [-1.63, -0.34]	_ - _
izquierdo et al. 2002	15	27.2	9	20	72	10	7.3%	-0.09 [-0.99, 0.82]	
Mujika et al. 2000	67	34.5	8	40	60.7	9	7.0%	0.51 [-0.46, 1.48]	
Skare et al. 2001	28	10.4	9	-2	27.7	9	6.7%	1.37 [0.31, 2.42]	
Subtotal (95% CI)			91			92	58.2%	0.47 [-0.22, 1.15]	-
Heterogeneity: Tau ² =	0.77; Ch	i ² = 33	.47, df	= 7 (P <	0.0001	L); I ² = 7	9%		
Test for overall effect:	Z = 1.33	(P = 0	.18)						
Total (95% CI)			150			150	100.0%	0.41 [-0.08, 0.90]	★
Heterogeneity: Tau ² =	0.63; Ch	i ² = 51	.42, df	= 13 (P	< 0.000	001); I ²	= 75%		
Test for overall effect:	Z = 1.65	(P = 0)	.10)	- (-					-2 -1 0 1 2
Test for subgroup diffe	rences.	Chi ² =	0.06.d	f = 1 (P)	= 0.80)	$1^2 = 0.9$	6		Favors Placebo Favors Creatine

Figure 3. A forest plot of studies that have investigated the effects of short-term creatine supplementation on peak power output during a repeated sprint test. Squares represent the standardized mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The plot includes subgroup analyses of studies that used cycling versus running as the mode of exercise. The size of each square reflects the weighting given to each response. The diamond at the base of the plot (and at the base of each subgroup analysis) represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

	Creatine			P	Placebo			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
1.12.1 Cycling										
Dawson et al. 1995	41.7	42	11	-19.5	78.3	11	13.7%	0.94 [0.05, 1.83]		
Griffen et al. 2015	5	43	9	-16	123	9	12.9%	0.22 [-0.71, 1.14]		
Kamber et al. 1999 Subtotal (95% CI)	32	8.9	10 30	7	23.7	10 30	11.6% 38.3 %	1.34 [0.35, 2.33] 0.82 [0.19, 1.45]		
Heterogeneity: Tau ² =	0.08; Ch	i ² = 2.	74, df :	= 2 (P =	0.25); I	² = 27%				
Test for overall effect:	Z = 2.54	(P = C	.01)							
1.12.2 Running										
Bogdanis et al. 2022	18.9	20.9	8	-2.9	36.9	8	11.2%	0.69 [-0.33, 1.70]		
Deminice et al. 2013	77.7	30	13	34.7	40.1	12	14.4%	1.18 [0.32, 2.04]	-	
Glaister et al. 2006	37	17.4	21	16	108.8	21	22.7%	0.26 [-0.34, 0.87]		
Izquierdo et al. 2002	27	53.3	9	30	76	10	13.5%	-0.04 [-0.94, 0.86]		
Subtotal (95% CI)			51			51	61.7%	0.49 [-0.01, 0.99]		
Heterogeneity: Tau ² =	0.09; Ch	i ² = 4.	48, df :	= 3 (P =	0.21); I	² = 33%	,			
Test for overall effect:	Z = 1.91	(P = C	.06)							
Total (95% CI)			81			81	100.0%	0.61 [0.23, 1.00]	-	
Heterogeneity: Tau ² =	0.07; Ch	i ² = 8.	24, df :	= 6 (P =	0.22); I	² = 27%	,	-		
Test for overall effect:	Z = 3.14	(P = 0	.002)						-2 -1 U I 2	
Test for subgroup differences: Chi ² = 0.63, df = 1 (P = 0.43), l ² = 0%										

Figure 4. A forest plot of studies that have investigated the effects of short-term creatine supplementation on mean power output during a repeated sprint test. Squares represent the standardized mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The plot includes subgroup analyses of studies that used cycling versus running as the mode of exercise. The size of each square reflects the weighting given to each response. The diamond at the base of the plot (and at the base of each subgroup analysis) represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

	Cr	eatine		Placebo				Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ahmun et al. 2005	0.2	16.3	14	1.1	6.9	14	15.9%	-0.07 [-0.81, 0.67]	
Ahmun et al. 2005	-1	3.7	14	-0.9	4	14	15.9%	-0.03 [-0.77, 0.72]	
Bogdanis et al. 2022	-2.1	3.6	8	-0.3	3.4	8	8.8%	-0.49 [-1.49, 0.51]	
Dawson et al. 1995	0.4	2.9	11	0.4	3.5	11	12.5%	0.00 [-0.84, 0.84]	
Delecluse et al. 2003	-0.3	1.3	9	-1.3	2.1	9	9.8%	0.55 [-0.40, 1.49]	
Deminice et al. 2013	-1.5	2	13	-1.1	1	12	14.1%	-0.24 [-1.03, 0.55]	
Glaister et al. 2006	0.2	2.8	21	-1.3	3.1	21	23.1%	0.50 [-0.12, 1.11]	
Total (95% CI)			90			89	100.0%	0.08 [-0.22, 0.37]	-
Heterogeneity: Tau ² =	0.00; Chi								
Test for overall effect:	Z = 0.51	-1 -0.5 0 0.5 1 Favors Creatine Favors Placebo							

Figure 5. A forest plot of studies that have investigated the effects of short-term creatine supplementation on fatigue percentage during a repeated sprint test. Squares represent the standardized mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to each response. The diamond at the base of the plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

	Creatine			Placebo				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Barnett et al. 1996	2.07	3.22	9	1.15	4.67	8	4.4%	0.92 [-2.94, 4.78]	•
Bogdanis et al. 2022	0.6	1.97	8	1.1	2.6	8	12.8%	-0.50 [-2.76, 1.76]	
Dawson et al. 1995	0.5	6.12	11	1.5	7.33	11	2.1%	-1.00 [-6.64, 4.64]	
Kamber et al. 1999	-0.9	2.5	10	0.1	2.79	10	12.2%	-1.00 [-3.32, 1.32]	
Kinugasa et al. 2004	1	3.38	6	0.7	1.91	6	6.8%	0.30 [-2.81, 3.41]	
Mujika et al. 2000	0	1.28	8	-0.4	1.08	9	51.0%	0.40 [-0.73, 1.53]	
Skare et al. 2001	1.5	2.5	9	0	2.84	9	10.7%	1.50 [-0.97, 3.97]	
Total (95% CI)			61			61	100.0%	0.22 [-0.59, 1.03]	◆
Heterogeneity: Tau ² = Test for overall effect:	0.00; Ch Z = 0.53	i ² = 2.8 (P = 0	-4 -2 0 2 4 Favors Creatine Favors Placebo						

Figure 6. A forest plot of studies that have investigated the effects of short-term creatine supplementation on blood lactate concentration at the end of a repeated sprint test. Squares represent the mean difference in change scores (post supplementation – baseline), relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to each response. The diamond at the base of the plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.